Bristol Myers, Dr. Reddy's Settle Revlimid Patent Suits
Bristol-Myers Squibb unit Celgene will permit Dr. Reddy's Laboratories Ltd. to sell a generic version of its cancer drug Revlimid on a limited basis after March 2022 and then an unlimited...To view the full article, register now.
Already a subscriber? Click here to view full article